Literature DB >> 22971957

Sustained high plasma mannose less sensitive to fluctuating blood glucose in glycogen storage disease type Ia children.

Hironori Nagasaka1, Tohru Yorifuji, Robert H J Bandsma, Tomozumi Takatani, Hisaki Asano, Hiroshi Mochizuki, Mayuko Takuwa, Hirokazu Tsukahara, Ayano Inui, Tomoyuki Tsunoda, Haruki Komatsu, Eitaro Hiejima, Tomoo Fujisawa, Ken-Ichi Hirano, Takashi Miida, Akira Ohtake, Tadao Taguchi, Ichitomo Miwa.   

Abstract

Plasma mannose is suggested to be largely generated from liver glycogen-oriented glucose-6-phosphate. This study examined plasma mannose in glycogen storage disease type Ia (GSD Ia) lacking conversion of glucose-6-phosphate to glucose in the liver. We initially examined fasting--and postprandial 2 h--plasma mannose and other blood carbohydrates and lipids for seven GSD Ia children receiving dietary interventions using cornstarch and six healthy age-matched children. Next, one-day successive intra-individual parameter changes were examined for six affected and two control children. Although there were no significant differences in fasting--and postprandial 2 h--glucose and insulin levels, the mannose level of the affected group was invariably much higher than that of the control group (p < 0.001): the fasting level of the affected group was about two-fold that of the control group; the postprandial-2 h level remained almost unchanged in the affected group, although it was one-half of the fasting level in the control group. Inter-individual analyses revealed that the GSD Ia group mannose level was significantly and positively correlated with lactate and triglycerides levels at both time points (p < 0.01). In each control, mannose levels fluctuated greatly, maintaining strong and significant negative correlations with glucose and insulin levels (p < 0.001). Correlations were lower or nonexistent in GSD Ia children. In individuals with high lactate and triglycerides levels, strikingly high mannose levels never changed against glucose and insulin fluctuations. Plasma mannose is less sensitive to blood glucose and insulin in GSD Ia children. Its basal level and the fluctuation pattern differ by their metabolic activity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22971957     DOI: 10.1007/s10545-012-9514-x

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  20 in total

1.  Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I).

Authors:  Jan Peter Rake; Gepke Visser; Philippe Labrune; James V Leonard; Kurt Ullrich; G Peter A Smit
Journal:  Eur J Pediatr       Date:  2002-08-22       Impact factor: 3.183

2.  Low level of fasting plasma mannose in a child with glycogen storage disease type 0 (liver glycogen synthase deficiency).

Authors:  Ichitomo Miwa; Tadao Taguchi; Hisaki Asano; Tomiyasu Murata; Tohru Yorifuji; Hironori Nagasaka; Tomozumi Takatani
Journal:  Clin Chim Acta       Date:  2010-03-21       Impact factor: 3.786

3.  Natural history of hepatocellular adenoma formation in glycogen storage disease type I.

Authors:  David Q Wang; Laurie M Fiske; Caroline T Carreras; David A Weinstein
Journal:  J Pediatr       Date:  2011-04-09       Impact factor: 4.406

Review 4.  Nutritional management of glycogen storage disease.

Authors:  P H Parker; M Ballew; H L Greene
Journal:  Annu Rev Nutr       Date:  1993       Impact factor: 11.848

5.  Downregulation of hepatic glucose-6-phosphatase-α in patients with hepatic steatosis.

Authors:  Sarah Konopelska; Tina Kienitz; Marcus Quinkler
Journal:  Obesity (Silver Spring)       Date:  2011-05-19       Impact factor: 5.002

6.  Carbohydrate-deficient glycoprotein syndrome type Ib. Phosphomannose isomerase deficiency and mannose therapy.

Authors:  R Niehues; M Hasilik; G Alton; C Körner; M Schiebe-Sukumar; H G Koch; K P Zimmer; R Wu; E Harms; K Reiter; K von Figura; H H Freeze; H K Harms; T Marquardt
Journal:  J Clin Invest       Date:  1998-04-01       Impact factor: 14.808

7.  Increased de novo lipogenesis and delayed conversion of large VLDL into intermediate density lipoprotein particles contribute to hyperlipidemia in glycogen storage disease type 1a.

Authors:  Robert H J Bandsma; Berthil H Prinsen; Monique de Sain van Der Velden; Jan-Peter Rake; Theo Boer; G Peter A Smit; Dirk-Jan Reijngoud; Folkert Kuipers
Journal:  Pediatr Res       Date:  2008-06       Impact factor: 3.756

8.  Tumor-targeted intracellular delivery of anticancer drugs through the mannose-6-phosphate/insulin-like growth factor II receptor.

Authors:  Jai Prakash; Leonie Beljaars; Akshay K Harapanahalli; Mieke Zeinstra-Smith; Alie de Jager-Krikken; Martin Hessing; Herman Steen; Klaas Poelstra
Journal:  Int J Cancer       Date:  2010-04-15       Impact factor: 7.396

9.  Mannose in body fluids as an indicator of invasive candidiasis.

Authors:  T P Monson; K P Wilkinson
Journal:  J Clin Microbiol       Date:  1981-11       Impact factor: 5.948

10.  Low-Km mannose-6-phosphatase as a criterion for microsomal integrity.

Authors:  B A Pederson; J D Foster; R C Nordlie
Journal:  Biochem Cell Biol       Date:  1998       Impact factor: 3.626

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.